Carranco DJA

Language: Spanish
References: 19
Page: 91-94
PDF size: 113.23 Kb.

ABSTRACT

Recent information suggests that up to 80% of patients with influenza A H1N1 (2009) continue to shed the virus at day 5, 40% at day 7, and 10% at day 10. It has also been described that children and young adults can shed virus for 10 or more days, and immunosupressed patients can shed the virus even for weeks; it has not been established the exact shedding period in this patients. We present a patient with acute lymphoblastic leukemia infected with influenza A H1N1 (2009) in whom we documented viral shedding for over three weeks.

REFERENCES

1. Maines TR, Jayaraman A, Belser JA et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 2009; 325: 484-487.

2. Munster VJ, de Wit E, van den Brand JM et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science. 2009; 325: 481-483.

3. Itoh Y, Shinya K, Kiso M et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009; 460: 1021-1025.

4. Gooskens J, Jonges M, Claas EC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis. 2009; 199 (10): 1435-1441.

5. Ling LM, Chow AL, Lye DC, Tan AS. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A H1N1 virus infection. Clin Infect Dis. 2010; 50: 963-969.

6. Aoki FY, Boivin G. Influenza virus shedding: excretion patterns and effects of antiviral treatment. J Clin Virol. 2009; 44: 255-261.

7. World Health Organization. Global Alert and Response (GAR); Pandemic (H1N1) 2009-Update. World Health Organization, 2009.

8. Sullivan SJ, Jacobson RM, Dowdle WR, Poland GA. 2009 H1N1 influenza. Mayo Clin Proc. 2010; 85 (1): 64-76.

9. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis. 1995; 172 (5): 1352-1355.

10. Ng S, Cowling BJ, Fang VJ. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis. 2010; 50 (5): 707-714.

11. To KK, Hung IF, Li IW. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010; 50 (6): 850-859.

12. Jain S, Kamimoto L. The 2009 pandemic influenza A (H1N1) virus hospitalization investigation team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009; 361: 1935-1944.

13. Li IW, Hung IF, To KK. The natural viral load profile of patients with pandemic 2009 influenza A (H1N1) and the effect of oseltamivir treatment. Chest. 2010; 137 (4): 759-768.

14. Ryoo et al. Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days. Influenza Other Respir Viruses. 2013; 7 (5): 833-837.

15. Redelman-Sidi G, Sepkowitz KA. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect. 2010; 60: 257-263.

16. Dulek DE, Williams JV, Creech CB. Use of intravenous zanamivir after development of Oseltamivir resistance in critically ill immunosuppressed child infected with influenza A H1N1 virus. Clin Infect Dis. 2010; 50 (11): 1493-1496.

17. Heneghan CJ, Onakpoya I. Zanamivir for influenza in adults and children: systematic review of clinical stufy reports. BMJ. 2014; 348: g2547.

18. Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev. 2009; (2):CD006484.

19. McManus M, Frangoul H. Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014; 61: 815-820.